Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.6% |
| 2 | Technology | 19.83% |
| 3 | Financials | 7.37% |
| 4 | Consumer Discretionary | 6.6% |
| 5 | Communication Services | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4101
State Street SPDR S&P Aerospace & Defense ETF
XAR
$5.59B
| $229K | ﹤0.01% |
1,085
+125
| +13% | +$22.7K |
2020 Q2
20 quarters
|
|
|
ACTU
4102
Actuate Therapeutics
ACTU
$19.7M
| $228K | ﹤0.01% |
+37,334
| New | +$326K |
2025 Q2
0 quarters
|
|
4103
Dynagas LNG Partners
DLNG
$137M
| $228K | ﹤0.01% |
64,800
| – | – |
2020 Q2
20 quarters
|
|
4104
Ohio Valley Banc Corp
OVBC
$210M
| $227K | ﹤0.01% |
+7,041
| New | +$234K |
2025 Q2
0 quarters
|
|
4105
BK Technologies
BKTI
$286M
| $226K | ﹤0.01% |
4,802
+4,717
| +5,549% | +$211K |
2024 Q4
2 quarters
|
|
|
VTYX
4106
DELISTED
Ventyx Biosciences
VTYX
| $226K | ﹤0.01% |
105,397
+44,034
| +72% | +$71.1K |
2022 Q1
13 quarters
|
|
|
CIRC
4107
Circle8 Group
CIRC
$58.4M
| $225K | ﹤0.01% |
+110,899
| New | +$334K |
2025 Q2
0 quarters
|
|
4108
CALL
Teladoc Health
TDOC
$1B
| $224K | ﹤0.01% |
25,700
| – | – |
2024 Q2
4 quarters
|
|
4109
Eastern Company
EML
$148M
| $223K | ﹤0.01% |
9,784
+4,537
| +86% | +$102K |
2024 Q2
4 quarters
|
|
4110
ECB Bancorp
ECBK
$179M
| $223K | ﹤0.01% |
14,455
+14,399
| +25,713% | +$226K |
2024 Q3
3 quarters
|
|
4111
InMode
INMD
$811M
| $223K | ﹤0.01% |
15,449
-99,938
| -87% | -$1.47M |
2022 Q1
13 quarters
|
|
4112
Aclaris Therapeutics
ACRS
$646M
| $222K | ﹤0.01% |
156,337
+37,336
| +31% | +$50.5K |
2019 Q1
25 quarters
|
|
4113
Comp X International
CIX
$461M
| $222K | ﹤0.01% |
8,347
+1,158
| +16% | +$28.6K |
2017 Q3
31 quarters
|
|
4114
Lifeway Foods
LWAY
$320M
| $221K | ﹤0.01% |
8,978
+4,089
| +84% | +$96.9K |
2023 Q4
6 quarters
|
|
4115
Tucows
TCX
$105M
| $221K | ﹤0.01% |
11,223
+2,547
| +29% | +$45.6K |
2017 Q2
32 quarters
|
|
4116
Neuronetics
STIM
$165M
| $221K | ﹤0.01% |
+63,380
| New | +$250K |
2025 Q2
0 quarters
|
|
4117
Maui Land & Pineapple Co
MLP
$312M
| $221K | ﹤0.01% |
12,143
+3,915
| +48% | +$63.5K |
2019 Q1
25 quarters
|
|
4118
LENSAR
LNSR
$82.9M
| $221K | ﹤0.01% |
+16,770
| New | +$226K |
2025 Q2
0 quarters
|
|
4119
FT Vest US Equity Enhance & Moderate Buffer ETF March
XMAR
$155M
| $221K | ﹤0.01% |
5,765
+1,775
| +44% | +$65.7K |
2024 Q3
3 quarters
|
|
|
RDFN
4120
DELISTED
Redfin
RDFN
| $220K | ﹤0.01% |
19,654
-511,699
| -96% | -$5.02M |
2017 Q3
31 quarters
|
|
|
DRUG
4121
Bright Minds Biosciences
DRUG
$500M
| $219K | ﹤0.01% |
+8,393
| New | +$252K |
2025 Q2
0 quarters
|
|
4122
Motley Fool 100 Index ETF
TMFC
$2.12B
| $218K | ﹤0.01% |
3,387
| – | – |
2021 Q2
16 quarters
|
|
|
CVAC
4123
DELISTED
CureVac
CVAC
| $218K | ﹤0.01% |
40,193
+1,949
| +5% | +$7.73K |
2024 Q3
3 quarters
|
|
4124
Landmark Bancorp
LARK
$191M
| $218K | ﹤0.01% |
+8,646
| New | +$231K |
2025 Q2
0 quarters
|
|
4125
Coherus Oncology
CHRS
$179M
| $218K | ﹤0.01% |
297,692
+66,702
| +29% | +$57.6K |
2014 Q4
42 quarters
|
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2025 filing shows 461 new, 2,914 increased, 1,345 reduced and 463 closed positions. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M. The largest sale was Honeywell, an estimated $1.54B.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 41% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.